New Ultrasensitive Blood Test Detects Advanced Tau Pathology in Alzheimer’s Disease

“I think scalability is the next step,” said Nicholas Ashton, PhD, senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute in Sun City, Arizona, describing a new blood test for advanced Alzheimer’s disease.

The assay, an ultrasensitive immunoassay that detects a tau protein fragment known as eMTBR-tau, was unveiled at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference and appeared online on November 16 in JAMA.

The finding matters because it moves a promising biomarker out of the laboratory bottleneck. Until now, plasma eMTBR-tau243 — a marker of the insoluble tau tangles that track neurodegeneration and cognitive decline — could only be measured by mass spectrometry, which is available in relatively few laboratories. The new assay, developed by Ashton in collaboration with Alamar Biosciences, Inc., requires just 35 µL of plasma compared with 1.5 mL for mass spectrometry.

In Plain English: The Clinical Takeaway

  • Existing blood tests like p-tau217 mostly identify earlier Alzheimer’s-related changes; this new test aims at late-stage tau tangles, which track how far the disease has progressed.
  • The test is not yet available for routine diagnosis. Larger studies are needed to establish clinical cutoffs before it reaches clinics.
  • Researchers see the two markers as complements, not competitors — one identifies Alzheimer’s biology, the other may stage its severity.

Why tau tangles tell a different story than plaques

Alzheimer’s disease is defined by two pathological signatures: amyloid-beta plaques and neurofibrillary tangles made up of aggregated tau protein. Blood tests measuring phosphorylated tau 217 (p-tau217) can detect Alzheimer’s-related amyloid pathology, but they offer less insight into how extensively tau tangles have accumulated — a factor more tightly linked to cognitive impairment and disease severity.

The new study tested whether a simpler, scalable immunoassay could match mass spectrometry at detecting eMTBR-tau, a fragment of tau protein that earlier studies in 2025 and 2026 linked to tau accumulation and faster cognitive decline.

New Ultrasensitive Blood Test Detects Advanced Tau Pathology in Alzheimer's Disease
Photo: Inside Precision Medicine

521 brain donors and two imaging cohorts put the assay to the test

The assay was assessed in a study involving 521 brain donors whose blood samples had been drawn before death as part of two US autopsy cohorts, along with 207 participants drawn from two tau PET imaging cohorts. In both autopsy cohorts, plasma eMTBR-tau concentrations rose sharply as neurofibrillary tangle pathology advanced, especially at Braak stages V and VI, when tau pathology has extended into the neocortex.

The scale of the difference is the headline number. At Braak stage VI, eMTBR-tau levels exceeded those at stages I-II by 50.5-fold and 25.2-fold in the two cohorts, respectively. For p-tau217, the corresponding increases were considerably smaller, at 4.6-fold and 3.2-fold.

In one of the autopsy cohorts, eMTBR-tau also outperformed p-tau217 significantly in separating advanced Braak stages from earlier ones, achieving an area under the curve (AUC) of 0.93 vs 0.84. In the second cohort, the difference was not statistically significant after adjustment.

Findings from the tau-PET imaging cohorts reinforced the neuropathologic results. In the 99-participant TRIAD cohort, eMTBR-tau concentrations were almost 60-fold greater at tau-PET Braak stages V-VI than at stage 0, versus a 4.9-fold rise for p-tau217.

In the BioFINDER-2 cohort, the immunoassay corresponded closely with mass spectrometry measurements (correlation coefficient, 0.93 overall and 0.96 among amyloid-positive participants), and the two methods detected regional tau-PET positivity with comparably high accuracy, with AUCs spanning 0.96 to 0.99 for the immunoassay and 0.97 to 0.99 for mass spectrometry.

Where the two markers may work together

Commenting on the findings, Marcal framed the two biomarkers as complementary.

“P-tau217 and eMTBR-tau are likely complementary, and there may eventually be a series or panel that could measure and help with staging of someone’s underlying biology.”

“P-tau217 helps identify Alzheimer’s pathology, while eMTBR-tau may provide additional information about tau burden and disease stage,” she said. Together, they could help doctors make better treatment decisions and identify the right patients for clinical trials.

Ashton emphasized that it’s “late-stage tau that we’re detecting through this biomarker,” adding, “I still think we’re missing that sensitivity, or maybe missing that novel biomarker for the earlier [Braak] stage regions.”

The investigators acknowledged several limitations, including the cross-sectional design, relatively small imaging cohorts, limited racial and ethnic diversity, and many eMTBR-tau values at early Braak stages falling below the assay’s lower limit of quantification. Larger prospective studies will be required to define clinical cutoffs, establish whether the test forecasts cognitive decline or treatment response, and confirm how it performs across different laboratories.

Who funded the research — and what was disclosed

The study was supported by multiple research grants and foundations. Bioventix supplied antibodies, and Alamar Biosciences performed immunoassay measurements. Ashton reported having advisory, educational, and consulting relationships with multiple companies, including Alamar Biosciences. Marcal reported having no disclosures.

Contraindications & When to Consult a Doctor

This is a research-stage biomarker, not an approved diagnostic. No regulatory body — including the FDA in the United States or the EMA in Europe — has cleared eMTBR-tau blood testing for clinical use, and no clinical cutoffs exist. Patients should not seek out this test or change care based on it.

Anyone concerned about memory loss or cognitive decline should consult a physician or neurologist, who can order established evaluations. Existing blood biomarkers such as p-tau217, alongside cognitive testing and, where available, amyloid and tau PET imaging, remain the conservative path to assessment. No source in this reporting describes any patient-facing use of eMTBR-tau today.

A window toward staging Alzheimer’s by blood

At present, the immunoassay may hold the greatest value for broadening research into blood-based staging of AD, potentially serving as a complement to established biomarkers such as p-tau217, the investigators noted. Ashton said the smaller blood volume required could also support decentralized research and remote blood collection, although these applications require further study. Marcal pointed to the longer horizon.

“Ultimately, she said, “this progress opens a window of opportunity to go further, supporting staging and a more precise, personalized approach to Alzheimer’s and all other dementias.””

Down the line, a scalable test could enable researchers to stage Alzheimer’s disease and choose patients for clinical trials, especially in settings where tau-PET imaging is not accessible. Whether that happens depends on the prospective validation studies the investigators themselves say must come next.

References

  • JAMA — Study publication, online November 16
  • Medscape Medical News — “Blood Test May Offer New Window Into Alzheimer’s Progression”
  • Inside Precision Medicine — “New Blood Test Could Make Measuring Advanced Alzheimer’s Disease More Accessible”

Consult a qualified healthcare professional regarding any concerns about Alzheimer’s disease or cognitive health.

Photo of author

Health Desk

Health Desk at Archyde.

Denmark Approves Trilateral Security Deal with U.S. and Greenland to Expand Arctic Military Presence